Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar Products

Alvotech and LOTTE Biologics have entered into a long-term strategic manufacturing partnership to produce multiple antibody biosimilar products at LOTTE's Syracuse facility in New York. This collaboration aims to enhance Alvotech's global manufacturing capacity and meet the growing demand for biosimilars. The Syracuse facility, which has a bioreactor capacity of 40,000 liters, has a proven track record in commercial biologics manufacturing and recently passed an FDA inspection with no observations.